国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (5): 350-355.doi: 10.3760/cma.j.issn.1673-422X.2016.05.008

• 论著 • 上一篇    下一篇

Runx3和CHD5基因在结直肠癌中的表达及临床意义

马栋,孙学军   

  1. 710061 西安交通大学第一附属医院普外科（马栋、孙学军）；陕西省安康市中心医院普外科（马栋）
  • 出版日期:2016-05-08 发布日期:2016-04-07
  • 通讯作者: 孙学军 E-mail:sunxy@mail.xjtu.edu.cn
  • 基金资助:

    国家自然科学基金（81172362）； 陕西省科技统筹创新工程计划（2013KTCQ03-08）

Expressions and clinical significances of Runx3 and CHD5 in colorectal cancer

Ma Dong, Sun Xuejun   

  1. Department of General Surgery, First Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710061; Department of General Surgery, Ankang Central Hospital of Shaanxi Province, Ankang 725000, China
  • Online:2016-05-08 Published:2016-04-07
  • Contact: Sun Xuejun E-mail:sunxy@mail.xjtu.edu.cn

PDF

909

被引次数

1

摘要： 目的探讨Runt相关转录因子3(Runx3)和染色质解旋酶DNA结合蛋白5(CHD5)基因在结直肠癌组织中的表达及临床意义。方法采用实时荧光定量聚合酶链反应（qRTPCR）和Western blotting方法检测96例新鲜结直肠癌组织、对应的癌旁10 cm正常组织以及72例腺瘤中的Runx3和CHD5基因的表达，分析其与结直肠癌临床病理特征的关系以及诊断价值和预后关系。结果Runx3和CHD5 mRNA、蛋白在结直肠癌组织中的相对表达量为0.35±0.00、0.28±0.02和0.26±0.02、0.31±0.01，显著低于癌旁正常组织中的相对表达量0.95±0.02、0.92±0.02和0.89±0.03、0.93±0.02（t=2.36，P＜0.05；t=1.25，P＜0.05；t=1.37，P＜0.05；t=1.13，P＜0.05）以及腺瘤中的相对表达量0.89±0.02、0.90±0.02和0.85±0.02、0.87±0.04（t=2.27，P＜0.05；t=2.16，P＜0.05；t=1.25，P＜0.05；t=2.65，P＜0.05）。Runx3和CHD5的表达与结直肠癌TNM分期（χ2=4.65，P=0.031；χ2=7.89，P=0.005）、浸润深度（χ2=4.17，P=0.041；χ2=4.86，P=0.028）、淋巴结转移（χ2=4.20，P=0.040；χ2=7.02，P=0.008）以及分化程度（χ2=7.31，P=0.036；χ2=9.54，P=0.023）呈负相关。线性相关性分析显示两基因表达呈正相关（r=0.572，P=0.001）。受试者特征（ROC）曲线进行评价表明Runx3、CHD5在结直肠癌中具有诊断价值（曲线下面积分别为0.712、0.745，敏感性和特异性分别是45.9%、52.5%和83.6%、81.4%）。Runx3和CHD5均低表达组与其他患者组在总生存时间（χ2=8.156，P＜0.05）及无进展生存时间（χ2=6.325，P＜0.05）上的差异具有统计学意义。结论Runx3和CHD5在结直肠癌中低表达，两基因共同检测可以作为结直肠癌诊断靶标以及预后指标。

关键词: 结直肠肿瘤, 病理学, 临床, ROC曲线, Runx3, CHD5

Abstract: ObjectiveTo investigate the expressions and clinical significances of Runtdomainrelated 3 (Runx3) and chromodomain helicase DNAbinding protein 5 (CHD5) in colorectal cancer. MethodsNinetysix colorectal cancer tissue samples and matched adjacent normal tissues and 72 colorectal adenoma tissues were collected. Realtime quantitative polymerase chain reaction (qRTPCR) and Western blotting were used to detect the mRNA and protein expression of Runx3 and CHD5. The associations of Runx3 and CHD5 expression with clinical pathological characteristics, diagnostic value and prognosis relationship of patients were further analyzed. ResultsRunx3 and CHD5 relative expressions of mRNA and protein were 0.35±0.00, 0.28±0.02 and 0.26±0.02, 0.31±0.01, which were significantly lower than those in the matched adjacent tissues 0.95±0.02, 0.92±0.02 and 0.89±0.03, 0.93±0.02 (t=2.36, P＜0.05; t=1.25, P＜0.05; t=1.37, P＜0.05; t=1.13, P＜0.05) and colorectal adenoma tissues 0.89±0.02, 0.90±0.02 and 0.85±0.02, 0.87±0.04 (t=2.27, P＜0.05; t=2.16, P＜0.05; t=1.25, P＜0.05; t=2.65, P＜0.05). Runx3 and CHD5 expressions differed significantly between tumors with different TNM stages (χ2=4.65, P=0.031; χ2=7.89, P=0.005), depths of tumor invasion (χ2=4.17, P=0.041; χ2=4.86, P=0.028), lymph node statuses (χ2=4.20, P=0.040; χ2=7.02, P=0.008), or histological differentiation (χ2=7.31, P=0.036; χ2=9.54, P=0.023). Linear correlation analysis showed that the expressions of the two genes were positively correlated (r=0.572, P=0.001). Receiver operating characteristic (ROC) curve showed that Runx3 and CHD5 had diagnostic value (AUC were 0.712, 0.745; sensitivity and specificity were 45.9%, 52.5% and 83.6%, 81.4% respectively). Runx3 and CHD5 both low expression group compared with the other patient groups in overall survival time (χ2=8.156， P＜0.05) and progressionfree survival (χ2=6.325, P<0.05) had statistically significant differences. ConclusionRunx3 and CHD5 are low expressed in colorectal cancer and may prove useful as biomarkers for diagnosis target and prognostic indication in patients with colorectal cancer.

Key words: Colorectal neoplasms, Pathology, clinical, ROC curve, Runx3, CHD5